First Indonesian Nasopharyngeal Cancer Whole Epigenome Sequencing Identify Tumour Suppressor CpG Methylation

Biologics, Journal Year: 2025, Volume and Issue: Volume 19, P. 1 - 13

Published: Jan. 1, 2025

Nasopharyngeal cancer (NPC) is a multifaceted disease characterized by genetic and epigenetic modifications. While Epstein-Barr virus (EBV) infection known risk factor, recent studies highlight the significant role of DNA methylation in NPC pathogenesis. Aberrant methylation, particularly at CpG sites, can silence tumour suppressor genes, promoting uncontrolled cell growth. This study aims to analyse patterns Indonesian patients through whole-epigenome sequencing. Seven clinical nasopharyngeal samples were collected confirmed histopathologically. was extracted, sequenced using Oxford Nanopore technology, aligned GRCh38 human reference genome. Methylation analysis performed modkit statistical with R software. Enriched pathways processes identified ClusterProfiler R, gene overlap conducted. The both globally hypermethylated hypomethylated samples. Key such as PRKCB, PLCB3, ITGB3, EPHA2, PLCE1, PRKCD, CDKN2A, CDKN2B, RPS6KA2, ERBB4, LRRC4, AKT1, PPP2R5C, STK11 frequently have lower expression an independent transcriptome cohort, suggesting their carcinogenesis. KEGG included PI3K-Akt signalling, ECM-receptor interaction, focal adhesion. presence EBV all samples, implicating its influencing patterns. provides comprehensive insights into landscape NPC, underscoring silencing. These findings pave way for targeted therapies need region-specific approaches management.

Language: Английский

The Association of Childhood Allergic Diseases with Prenatal Exposure to Pollen Grains Through At-Birth DNA Methylation

Epigenomes, Journal Year: 2025, Volume and Issue: 9(1), P. 9 - 9

Published: March 11, 2025

Background: Pollen exposure in early life is shown to be associated with allergy and asthma. DNA methylation (DNAm), an epigenetic marker, potentially reacts pollen. However, the role of at-birth DNAm between prenatal pollen grain (PPG) childhood asthma allergic rhinitis unknown. Methods: Data a birth cohort study on Isle Wight, UK, were analyzed (n = 236). Newborn was measured cord blood or spots Guthrie cards screened for potential association PPG using R package ttScreening. CpGs that passed screening further assessed such associations via linear regressions adjusting covariates included. Finally, at PPG-associated evaluated their logistic regressions, covariates. The impact cell heterogeneity findings assessed. Statistical significance set p < 0.05. Results: In total, 42 screening, 41 remaining statistically significant after types (p 0.05). High lower cg12318501 (ZNF99, β −0.029, 0.032) cg00929606 (ADM2, −0.023, 0.008), which subsequently decreased odds (OR 0.11, 95% CI 0.02–0.53, 0.006; OR 0.14, 0.02–1.00, 0.049). For rhinitis, cg15790214 (HCG11) play as mediator (β −0.027, ≤ 0.0001; 0.22, 0.07–0.72, 0.01). Conclusions: incidence mediated by birth.

Language: Английский

Restoration of Skin Barrier Abnormalities with IL4/13 Inhibitors and Jak Inhibitors in Atopic Dermatitis: A Systematic Review

Medicina, Journal Year: 2024, Volume and Issue: 60(8), P. 1376 - 1376

Published: Aug. 22, 2024

Background and Objectives: Atopic dermatitis is a chronic inflammatory skin disorder with significant burden on patients’ quality of life. This systematic review aims to evaluate the restoration barrier abnormalities interleukin-4/interleukin-13 (IL-4/IL-13) inhibitors Janus kinase (JAK) in atopic dermatitis. Materials Methods: A comprehensive literature was conducted, focusing studies that assess use IL-4/IL-13 JAK for We identified eligible by searching Medline via PubMed special focus their effect epidermal barrier. Included evaluated transepidermal water loss (TEWL), reduction thickness (ET), improvement ceramide synthesis, increase stratum corneum hydration (SCH) inhibitors. The included assessed using ROBINS-I RoB 2.0 tool assessing risk bias. Results: Ten concern dupilumab, while two were observational randomized controlled trials (RCTs). total number participants 378 concerning dupilumab 38 Five did not include any comparison group, three healthy volunteers, conducted versus placebo, compared other treatments. follow-up period ranged between 29 days 32 weeks. results demonstrated decrease (TEWL) an SCH eczematous lesions patients sustained response treatment observed improvements ET filaggrin (FLG) staining, which further support efficacy enhancing function. Conclusions: underscores improving However, limited overall lack RCTs highlight need research establish definitive role

Language: Английский